Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, is currently focused on developing groundbreaking cancer therapies. At the forefront of the company's research are its two main drug candidates – SNDX-5613 and SNDX-6352. SNDX-5613 just entered phase 1/2 of clinical trials to combat KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1) by targeting the binding interaction of Menin with the mixed lineage leukemia 1. SNDX-6352, or axatilimab, is a monoclonal antibody that counteracts the colony stimulating factor 1 (CSF-1) receptor for treating patients with chronic graft versus host disease (cGVHD). Syndax is also working on the development of Entinostat, and has a licensing, development, and commercialization agreement with Eddingpharm International Company Limited. Syndax Pharmaceuticals was founded in 2005 and is headquartered in Waltham, Massachusetts.
Syndax Pharmaceuticals's ticker is SNDX
The company's shares trade on the NASDAQ stock exchange
They are based in Waltham, Massachusetts
There are 51-200 employees working at Syndax Pharmaceuticals
It is syndax.com
Syndax Pharmaceuticals is in the Healthcare sector
Syndax Pharmaceuticals is in the Biotechnology industry
The following five companies are Syndax Pharmaceuticals's industry peers: